中文
| Catalogue |
| Recommend Products |
Company News
- AMSBIO: Using Lentivectors to Label Organoids 7/1/2021
- AMSBIO: New iPSC Model for COVID-19 6/29/2021
- AMSBIO: A New iPSC Model for COVID-19 6/18/2021
- AMSBIO: Developing a Cell Therapy for Parkinson’s Disease 5/26/2021
- AMSBIO: Biotinylated Heparan Sulfate Antibodies 4/29/2021
- AMSBIO: Cytosections for Antibody Screening and Immunohistochemistry Protocol Development 4/15/2021
- AMSBIO: Animal-Free Enzymes for In-Vitro Tissue Dissociation 3/26/2021
- AMSBIO: GMP-Ready Helper Plasmids for AAV Production 3/18/2021
- AMSBIO Announce a New HER2 Control Breast Cancer Cell Line Array 3/4/2021
- AMSBIO: Mutant Spike Proteins & Antigens for SARS-CoV-2 Variant Research 2/18/2021
- AMSBIO: Patient-Derived Human Primary Cancer Cells 2/3/2021
- AMSBIO Launched the cfPure® Cell Free Nucleic Acid Extraction 1/20/2021
- AMSBIO: High-quality SARS-CoV-2 Antigen Protein Kits 1/6/2021
- AMSBIO: Novel Cell Therapy for Liver Cirrhosis 12/17/2020
- AMSBIO: Heparan Sulfate Products for COVID-19 Infection, Disease & Therapeu... 11/25/2020
- AMSBIO: Safeguarding Organoids Through Lockdown 11/12/2020
- AMSBIO: Custom Recombinant Monoclonal Antibody Development Service 10/28/2020
- AMSBIO: SARS-CoV-2 Antibodies and Antigens for Diagnostic Kit Development 10/19/2020
- AMSBIO: Powerful Human iPSC-derived Cells, Kits & Services 10/9/2020
- AMSBIO: Optimized Medium for Expansion of Mesenchymal Stem Cells 10/9/2020